AstraZeneca
Published: 03/04/2026
Headquarters: Cambridge, England
Website: Visit Website
Therapeutic Areas
- oncology
- immunology
- neurology
Pipeline Overview
Key pipeline highlights include:
- Enhertu (trastuzumab deruxtecan) — Recent Phase 3 approvals include DESTINY-Breast09 for HER2-positive metastatic breast cancer (1st line) in the US, and DESTINY-Breast06 for HER2-low and ultralow HR+ breast cancer in the EU, expanding Enhertu’s reach across the HER2 spectrum.
- Tagrisso (osimertinib) — Received EU approval in unresectable EGFRm NSCLC (LAURA trial), and met secondary overall survival endpoints in the FLAURA2 trial in 1st-line EGFRm NSCLC.
- Imfinzi (durvalumab) — Secured US approval in limited-stage small cell lung cancer (ADRIATIC trial) and EU/US approval in resectable gastric/GEJ cancer (MATTERHORN trial).
- Camizestrant — Met primary endpoint in the Phase 3 SERENA-6 trial for HR+/HER2- metastatic breast cancer, with results featured in the ASCO 2025 plenary session.
- Calquence (acalabrutinib) — Received approval in Japan for mantle cell lymphoma in both previously untreated and relapsed/refractory settings, with US approval in MCL (ECHO trial) also secured.
- Baxdrostat — Met primary endpoint in the BaxHTN trial for uncontrolled or treatment-resistant hypertension, representing a significant advance in the CVRM pipeline.
- Gefurulimab — Met primary endpoint in the PREVAIL trial for generalised myasthenia gravis, with regulatory submission accepted. s
Latest News
- AstraZeneca Announces $50 Billion Investment in the United States
- AstraZeneca Boosts U.S. Manufacturing with Record $4.5 Billion Investment in Virginia, Creating 3,600 Jobs
- AstraZeneca Delivers Robust 2025 Results as $58.7B Revenue as “Blockbuster” Portfolio Expands to 16 Medicines
- AstraZeneca Posts Strong Q3 Results, Citing 11% Revenue Growth in 2025 Driven by Oncology and Pipeline Success
- AstraZeneca Released KALOS and LOGOS Phase III Clinical Trials Result Shows Positive High-level Results of Breztri for Treating Asthma
- AstraZeneca Released Satisfactory Results of 24 Weeks CALYPSO Phase III Trial for Eneboparatide
- AstraZeneca Secures EU’s Approval for Fixed-Duration Calquence-Based Regimens in First-Line Chronic Lymphocytic Leukemia (CLL)
- AstraZeneca Strikes ‘Historic’ Drug Pricing Deal with US Government, Commits $50 Billion to US Manufacturing
- AstraZeneca’s Datroway Receives US Approval for EGFR-Mutated Lung Cancer
- AstraZeneca’s Gefurulimab Shows Major Promise in Late-Stage Myasthenia Gravis Trial
- AstraZeneca’s Imfinzi Gains EU Approval as First Perioperative Immunotherapy for High-Risk Bladder Cancer
- AstraZeneca’s Imfinzi Granted Priority Review by U.S. FDA for Gastric/GEJ Cancers
- AstraZeneca’s Imfinzi® Demonstrates Significant Improvement in Disease-Free Survival for Early-Stage Bladder Cancer Patients
- AstraZeneca’s Tagrisso Combination Therapy Sets New Survival Benchmark in Advanced Lung Cancer
- AstraZeneca’s Tagrisso with Chemotherapy Shows Significant Survival Benefit in Advanced Lung Cancer
- AstraZeneca’s Tezspire Gains EU Approval for Nasal Polyps, Offering New Hope for Patients
- AstraZeneca’s Breztri Triple-Therapy Hits Primary Goals in Landmark Phase III Asthma Trials
Discover More
